

**Policy: MP241**

**Section: Medical Benefit Policy**

**Subject: Non-invasive Measurement of Advanced Glycation End-products**

### Applicable Lines of Business

<b>Commercial</b>	<b>X</b>	<b>CHIP</b>	<b>X</b>
<b>Medicare</b>	<b>X</b>	<b>ACA</b>	<b>X</b>
<b>Medicaid</b>	<b>X</b>		

### I. Policy: Non-invasive Measurement of Advanced Glycation End-products

#### II. Purpose/Objective:

To provide a policy of coverage regarding Non-invasive Measurement of Advanced Glycation End-products

#### III. Responsibility:

- A. Medical Directors
- B. Medical Management

#### IV. Required Definitions

1. Attachment – a supporting document that is developed and maintained by the policy writer or department requiring/authoring the policy.
2. Exhibit – a supporting document developed and maintained in a department other than the department requiring/authoring the policy.
3. Devised – the date the policy was implemented.
4. Revised – the date of every revision to the policy, including typographical and grammatical changes.
5. Reviewed – the date documenting the annual review if the policy has no revisions necessary.

#### V. Additional Definitions

Medical Necessity or Medically Necessary means Covered Services rendered by a Health Care Provider that the Plan determines are:

- a. appropriate for the symptoms and diagnosis or treatment of the Member's condition, illness, disease or injury;
- b. provided for the diagnosis, and the direct care and treatment of the Member's condition, illness disease or injury;
- c. in accordance with current standards of good medical treatment practiced by the general medical community.
- d. not primarily for the convenience of the Member, or the Member's Health Care Provider; and
- e. the most appropriate source or level of service that can safely be provided to the Member. When applied to hospitalization, this further means that the Member requires acute care as an inpatient due to the nature of the services rendered or the Member's condition, and the Member cannot receive safe or adequate care as an outpatient.

#### Medicaid Business Segment

Medically Necessary — A service, item, procedure, or level of care that is necessary for the proper treatment or management of an illness, injury, or disability is one that:

- Will, or is reasonably expected to, prevent the onset of an illness, condition, injury or disability.
- Will, or is reasonably expected to, reduce or ameliorate the physical, mental or developmental effects of an illness, condition, injury or disability.

- Will assist the Member to achieve or maintain maximum functional capacity in performing daily activities, taking into account both the functional capacity of the Member and those functional capacities that are appropriate for Members of the same age

**DESCRIPTION:**

Advanced glycation end-products (AGE) are metabolic byproducts from non-enzymatic glycation of proteins and amino acids. They have been proposed as a biomarker for disease severity and risk prediction. Because AGEs demonstrate autofluorescence when exposed to particular wavelengths of light, spectrographic non-invasive autofluorescence readers have been developed and used to measure AGEs in the study of several disease such as but not limited to diabetes, renal failure and cardiac disease.

**EXCLUSIONS:**

There is insufficient evidence in the peer-reviewed published medical literature to establish the effectiveness of non-invasive measurement of advanced glycation end-products (AGEs) for any indication. Therefore, the Plan does **NOT** provide coverage for the measurement of AGEs because it is considered to be **experimental, investigational or unproven**.

Note: A complete description of the process by which a given technology or service is evaluated and determined to be experimental, investigational or unproven is outlined in **MP 15 - Experimental Investigational or Unproven Services or Treatment**.

**Medicaid Business Segment:**

Any requests for services, that do not meet criteria set in the PARP, may be evaluated on a case by case basis.

**CODING ASSOCIATED WITH:** Non-invasive Measurement of Advanced Glycation End-products

*The following codes are included below for informational purposes and may not be all inclusive. Inclusion of a procedure or device code(s) does not constitute or imply coverage nor does it imply or guarantee provider reimbursement. Coverage is determined by the member specific benefit plan document and any applicable laws regarding coverage of specific services.*

88749 unlisted in vivo (eg, transcutaneous) laboratory service

Current Procedural Terminology (CPT®) © American Medical Association: Chicago, IL

**LINE OF BUSINESS:**

**Eligibility and contract specific benefit limitations and/or exclusions will apply. Coverage statements found in the line of business specific benefit document will supersede this policy. For Medicare, applicable LCD's and NCD's will supercede this policy For PA Medicaid Business segment, this policy applies as written.**

**REFERENCES:**

Gerrits EG, Lutgers HL, Kleefstra N, et al. Skin autofluorescence: a tool to identify type 2 diabetic patients at risk for developing microvascular complications. Diabetes Care. 2008; 31(3):517-521.

Hartog JW, Gross S, Oterdoom LH, et al. Skin-autofluorescence is an independent predictor of graft loss in renal transplant recipients. Transplantation. 2009; 87(7):1069-1077.

Hartog JW, Hummel YM, Voors AA, et al. Skin-autofluorescence, a measure of tissue advanced glycation end-products (AGEs), is related to diastolic function in dialysis patients. J Card Fail. 2008; 14(7):596-602.

Lutgers HL, Gerrits EG, Graaff R, et al. Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus. Diabetologia. 2009; 52(5):789-797.

McIntyre NJ, Chesterton LJ, John SG, et al. Tissue-advanced glycation end product concentration in dialysis patients. Clin J Am Soc Nephrol. 2010; 5(1):51-55.

Nienhuis HL, de Leeuw K, Bijzet J, et al. Skin autofluorescence is increased in systemic lupus erythematosus but is not reflected by elevated plasma levels of advanced glycation endproducts. Rheumatology (Oxford). 2008; 47(10):1554-1558.

Ueno H, Koyama H, Tanaka S, et al. Skin autofluorescence, a marker for advanced glycation end product accumulation, is associated with arterial stiffness in patients with end-stage renal disease. Metabolism. 2008; 57(10):1452-1457.

American Diabetes Association. Standards of Medical Care in Diabetes—2010. *Diabetes Care*. 2010; 33:S11-S61. Available at [http://care.diabetesjournals.org/content/33/Supplement\\_1](http://care.diabetesjournals.org/content/33/Supplement_1). Accessed on July 7, 2010.

Llaurado G, Ceperuelo-Mallafre V, Vilardell C, et al. Advanced glycation end products are associated with arterial stiffness in type 1 diabetes. *J Endocrinol*. 2014;221(3):405-413

Banser A, Naafs JC, Hoorweg-Nijman JJ, et al. Advanced glycation end products, measured in skin, vs. HbA1c in children with type 1 diabetes mellitus. *Pediatr Diabetes*. 2015 Sep 2

Rajaobelina K, Farges B, Nov S, et al. Skin autofluorescence and peripheral neuropathy four years later in type 1 diabetes. *Diabetes Metab Res Rev*. 2016 May 27

Da Moura Semedo C, Webb M, Waller H, et al. Skin autofluorescence, a non-invasive marker of advanced glycation end products: Clinical relevance and limitations. *Postgrad Med J*. 2017;93(1099):289-294.

van Waateringe RP, Slagter SN, van Beek AP, et al. Skin autofluorescence, a non-invasive biomarker for advanced glycation end products, is associated with the metabolic syndrome and its individual components. *Diabetol Metab Syndr*. 2017;9:42

Stirban AO, Bondor CI, Florea B, et al. Skin autofluorescence: Correlation with measures of diabetic sensorimotor neuropathy. *J Diabetes Complications*. 2018;32(9):851-856

Varikasuvu SR, Sulekar H, Aloori S, Thangappazham B. The association of non-invasive skin autofluorescence measurements with cardiovascular and all-cause mortality in hemodialysis patients: A meta-analysis. *Int Urol Nephrol*. 2020;52(9):1757-1769.

Hofmann B, Gerull KA, Bloch K, et al. It's all in our skin -- skin autofluorescence -- a promising outcome predictor in cardiac surgery: A single centre cohort study. *PLoS One*. 2020;15(6):e0234847.

Lee J, Jeong ET, Lim J-M, Park SG. Development of the facial glycation imaging system for in situ human face skin glycation index measurement. *J Cosmet Dermatol*. 2021;20(9):2963-2968

Varikasuvu SR, Varshney S, Sulekar H. Skin autofluorescence as a novel and noninvasive technology for advanced glycation end products in diabetic foot ulcers: A systematic review and meta-analysis. *Adv Skin Wound Care*. 2021;34(11):1-8.

Lee J, Yun J-S, Ko S-H. Advanced glycation end products and their effect on vascular complications in type 2 diabetes mellitus. *Nutrients*. 2022;14(15):3086.

Li S, Li Y, Xu X, et al. Lens autofluorescence based advanced glycation end products (AGEs) measurement to assess risk of osteopenia among individuals under the age of 50. *Med Devices* 2022;15:341-347.

Aihara M, Jinnouchi H, Yoshida A, et al. Evaluation of glycated albumin levels in tears and saliva as a marker in patients with diabetes mellitus. *Diabetes Res Clin Pract*. 2023;199:110637.

This policy will be revised as necessary and reviewed no less than annually.

**Devised:** 7/12/10

**Revised:**

**Reviewed:** 7/11, 7/12, 7/13, 7/14, 7/15, 7/16, 6/17, 6/18, 6/19, 6/20, 6/21, 6/22, 6/23, 6/24

**CMS UM Oversight Committee Approval:** 12/23, 7/24

Geisinger Health Plan may refer collectively to health care coverage sponsors Geisinger Health Plan, Geisinger Quality Options, Inc., and Geisinger Indemnity Insurance Company, unless otherwise noted. Geisinger Health Plan is part of Geisinger, an integrated health care delivery and coverage organization.

Coverage for experimental or investigational treatments, services and procedures is specifically excluded under the member's certificate with Geisinger Health Plan. Unproven services outside of an approved clinical trial are also specifically excluded under the member's certificate with Geisinger Health Plan. This policy does not expand coverage to services or items specifically excluded from coverage in the member's certificate with Geisinger Health Plan. Additional information can be found in MP015 Experimental, Investigational or Unproven Services.

Prior authorization and/or pre-certification requirements for services or items may apply. Pre-certification lists may be found in the member's contract specific benefit document. Prior authorization requirements can be found at <https://www.geisinger.org/health-plan/providers/ghp-clinical-policies>

Please be advised that the use of the logos, service marks or names of Geisinger Health Plan, Geisinger Quality Options, Inc. and Geisinger Indemnity Insurance Company on a marketing, press releases or any communication piece regarding the contents of this medical policy is strictly prohibited without the prior written consent of Geisinger Health Plan. Additionally, the above medical policy does not confer any endorsement by Geisinger Health Plan, Geisinger Quality Options, Inc. and Geisinger Indemnity Insurance Company regarding the medical service, medical device or medical lab test described under this medical policy.